Amicus Therapeutics Inc (NASDAQ:FOLD) — Market Cap & Net Worth
Market Cap & Net Worth: Amicus Therapeutics Inc (FOLD)
Amicus Therapeutics Inc (NASDAQ:FOLD) has a market capitalization of $4.55 Billion ($4.55 Billion) as of September 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #3787 globally and #1326 in its home market, demonstrating a 0.21% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Amicus Therapeutics Inc's stock price $14.49 by its total outstanding shares 314000712 (314.00 Million). Also see how large is Amicus Therapeutics Inc's balance sheet for a full breakdown of the balance sheet.
Amicus Therapeutics Inc Market Cap History: 2015 to 2026
Amicus Therapeutics Inc's market capitalization history from 2015 to 2026. Data shows growth from $3.05 Billion to $4.55 Billion (7.30% CAGR). Also see how efficiently does Amicus Therapeutics Inc generate cash for how efficiently the company converts equity into cash flow.
Index Memberships
Amicus Therapeutics Inc is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.66 Trillion | 0.17% | #98 of 976 |
|
NASDAQ Composite
IXIC
|
$41.69 Trillion | 0.01% | #439 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.88 Trillion | 0.24% | #64 of 263 |
Weight: Amicus Therapeutics Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Amicus Therapeutics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Amicus Therapeutics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check FOLD stock price and chart for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
7.05x
Amicus Therapeutics Inc's market cap is 7.05 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $1.56 Billion | $4.96 Million | -$200.04 Million | 314.76x | N/A |
| 2017 | $4.52 Billion | $36.93 Million | -$284.00 Million | 122.35x | N/A |
| 2018 | $3.01 Billion | $91.25 Million | -$349.00 Million | 32.97x | N/A |
| 2019 | $3.06 Billion | $182.24 Million | -$356.39 Million | 16.78x | N/A |
| 2020 | $7.25 Billion | $260.89 Million | -$276.85 Million | 27.79x | N/A |
| 2021 | $3.63 Billion | $305.51 Million | -$250.46 Million | 11.87x | N/A |
| 2022 | $3.83 Billion | $329.23 Million | -$236.57 Million | 11.65x | N/A |
| 2023 | $4.46 Billion | $399.36 Million | -$151.58 Million | 11.16x | N/A |
| 2024 | $2.96 Billion | $528.29 Million | -$56.11 Million | 5.60x | N/A |
| 2025 | $4.47 Billion | $634.21 Million | -$27.11 Million | 7.05x | N/A |
Competitor Companies of FOLD by Market Capitalization
Companies near Amicus Therapeutics Inc in the global market cap rankings as of September 18, 2026. Review Amicus Therapeutics Inc (FOLD) tangible net worth to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Amicus Therapeutics Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #187 globally with a market cap of $130.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #353 globally with a market cap of $78.34 Billion USD.
- CSL Ltd (AU:CSL): Ranked #457 globally with a market cap of $59.87 Billion USD ( AU$84.62 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #505 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #187 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.09 Billion | $513.26 |
| #353 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $78.34 Billion | $774.61 |
| #457 | CSL Ltd | AU:CSL | $59.87 Billion | AU$174.41 |
| #505 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $145.62 |
Amicus Therapeutics Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, Amicus Therapeutics Inc's market cap moved from $3.05 Billion to $ 4.55 Billion, with a yearly change of 7.30%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $4.55 Billion | +1.76% |
| 2025 | $4.47 Billion | +51.17% |
| 2024 | $2.96 Billion | -33.62% |
| 2023 | $4.46 Billion | +16.22% |
| 2022 | $3.83 Billion | +5.71% |
| 2021 | $3.63 Billion | -49.98% |
| 2020 | $7.25 Billion | +137.06% |
| 2019 | $3.06 Billion | +1.67% |
| 2018 | $3.01 Billion | -33.43% |
| 2017 | $4.52 Billion | +189.54% |
| 2016 | $1.56 Billion | -48.76% |
| 2015 | $3.05 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 17th, 2026 the market cap of Amicus Therapeutics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $4.55 Billion USD |
| MoneyControl | $4.55 Billion USD |
| MarketWatch | $4.55 Billion USD |
| marketcap.company | $4.55 Billion USD |
| Reuters | $4.55 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Amicus Therapeutics Inc
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering novel medicines for rare diseases in the United States and internationally. The company's commercial product and product candidates consist of Galafold, an orally administered monotherapy for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha … Read more